


Introduction to cancer genetics and genomics

Nuria Lopez-Bigas

- Molecular bases of cancer
- Cancer alterations and technologies to detect them genome-wide
- Predictive cancer genomics
- NGS technologies in cancer research


Cancer-Associated Mutations



Artwork by Jeanne Kelly. © 2004.

- Oncogenes
- Tumor suppressor genes
- DNA repair genes
- Carcinogen
 - activating genes
 - deactivating genes
- Cell cycle genes
- Cell cycle checkpoint genes
- Cell death genes
- Cell signaling genes
- Cellular differentiation genes
- Cellular senescence genes
- Metastasis/invasion genes

Tumors Are Clonal




Artwork by Jeanne Kelly, © 2004.

Mutations: Somatic and Germline

Somatic mutations

- Occur in nongermline tissues
- Are nonheritable




Nonheritable

Somatic mutation
(e.g., breast)

Germline mutations

- Present in egg or sperm
- Are heritable
- Cause cancer family syndrome



Mutation in
egg or sperm

All cells
affected in
offspring

Mutations in Cancer Susceptibility Genes: *BRCA1*

■ On chromosome 17

■ Protein has role in
genomic stability

■ Autosomal dominant
transmission

■ ~500 different
mutations reported

Artwork by Jeanne Kelly, © 2004.




■ Nonsense/Frameshift

● Missense


◆ Splice-site

Hallmarks of Cancer




Hallmarks of Cancer

A

Component	Acquired Capability	Example of Mechanism
	Self-sufficiency in growth signals	Activate H-Ras oncogene
	Insensitivity to anti-growth signals	Lose retinoblastoma suppressor
	Evading apoptosis	Produce IGF survival factors
	Limitless replicative potential	Turn on telomerase
	Sustained angiogenesis	Produce VEGF inducer
	Tissue invasion & metastasis	Inactivate E-cadherin


B






Genomic and epigenomic aberrations in cancer


Genomic and epigenomic aberrations in cancer

consequences at the level of gene expression and protein function




High-throughput technologies to identify cancer alterations

Type of alteration	High-throughput technology
Transcriptomic alterations 	Expression microarrays
Point mutations 	Sequencing
Translocations 	SKY, FISH
Amplifications and deletions 	Comparative Genomics Hybridization
Epigenomic alterations 	Methylation profiling




Expression microarrays





Large Deletions or Insertions

SKY chromosome painting: breast cancer




Normal SKY chromosomes are not multicolored.

Chromosomes in breast cancer appear multicolored because they have exchanged genetic material.




Philadelphia Chromosome

chronic myelogenous leukemia




Artwork by Jeanne Kelly, © 2004.




Amplifications and deletions



Comparative Genomics Hybridization (CGH)




Amplifications and deletions




Comparative Genomics Hybridization (CGH)



Example: band specific frequency of genomic imbalances in breast carcinomas




Epigenomic alterations



Methylation Profiling







The Consensus Coding Sequences of Human Breast and Colorectal Cancers


Tobias Sjöblom,^{1*} Siân Jones,^{1*} Laura D. Wood,^{1*} D. Williams Parsons,^{1*} Jimmy Lin,¹ Thomas D. Barber,^{1†} Diana Mandelker,¹ Rebecca J. Leary,¹ Janine Ptak,¹ Natalie Silliman,¹ Steve Szabo,¹ Phillip Buckhaults,² Christopher Farrell,² Paul Meeh,² Sanford D. Markowitz,³ Joseph Willis,⁴ Dawn Dawson,⁴ James K. V. Willson,⁵ Adi F. Gazdar,⁶ James Hartigan,⁷ Leo Wu,⁸ Changsheng Liu,⁸ Giovanni Parmigiani,⁹ Ben Ho Park,¹⁰ Kurtis E. Bachman,¹¹ Nickolas Papadopoulos,¹ Bert Vogelstein,^{1‡} Kenneth W. Kinzler,^{1‡} Victor E. Velculescu^{1‡}

The elucidation of the human genome sequence has made it possible to identify genetic alterations in cancers in unprecedented detail. To begin a systematic analysis of such alterations, we determined the sequence of well-annotated human protein-coding genes in two common tumor types. Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ~90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology.


Point mutations




Detecting the Troublemakers




Drivers vs Passengers




Cancer genome characterization






Various alterations affecting the same pathway




Molecular Diagnostics of Cancer





Generating a prognostic gene-expression signature

a




b






Overall and relapse-free survival analysis of the 49 breast cancer patients, uniformly treated in a prospective study, based on different gene expression classification.




Sørli T et al. PNAS 2001;98:10869-10874


70 gene prognostic signature in breast cancer



70 gene prognostic signature in breast cancer




Oncotype DX: 21 gene signature in breast cancer for predicting distance recurrence



Oncotype DX: 21 gene signature in breast cancer for predicting distance recurrence


Distant Recurrence for the three distinct cohorts identified



Paik et al. *N Engl J Med.* 2004;351:2817-2826.

Oncotype DX: 21 gene signature in breast cancer for predicting distance recurrence

Recurrence Score in N-, ER+ patients



Lower RS's

- Lower likelihood of recurrence
- Greater magnitude of TAM benefit
- Minimal, if any, chemotherapy benefit

Higher RS's

- Greater likelihood of recurrence
- Lower magnitude of TAM benefit
- Clear chemotherapy benefit

1) Paik et al NEJM 2004, 2) Habel et al Breast Cancer Research 2006
3) Paik et al JCO 2006, 4) Gianni et al JCO 2005

PATIENTS & CAREGIVERS

HEALTHCARE PROFESSIONALS

MANAGED CARE ORGANIZATIONS

CUSTOMER SUPPORT




CHEMO? NO CHEMO?

The **Oncotype DX[®]** Breast Cancer Assay
helps you find an answer

oncotype DX[®]
Breast Cancer Assay

© 2010 Genomic Health, Inc.

Next Generation Sequencing Revolution



Basics of the “old” technology

- Clone the DNA.
- Generate a ladder of labeled (colored) molecules that are different by 1 nucleotide.
- Separate mixture on some matrix.
- Detect fluorochrome by laser.
- Interpret peaks as string of DNA.
- Strings are 500 to 1,000 letters long
- 1 machine generates 57,000 nucleotides/run
- Assemble all strings into a genome.

Basics of the “new” technology

- Get DNA.
- Attach it to something.
- Extend and amplify signal with some color scheme.
- Detect fluorochrome by microscopy.
- Interpret series of spots as short strings of DNA.
- Strings are 30-300 letters long
- Multiple images are interpreted as 0.4 to 1.2 GB/run (1,200,000,000 letters/day).
- Map or align strings to one or many genome.

Template preparation

- Clonally amplified templates from a single DNA molecule

 - Emulsion PCR

 - Solid Phase Amplification

- Single DNA molecule

 - Primer immobilized

 - Template immobilized

 - Polymerase immobilized

Sequencing

Imaging

Data processing

Template preparation

Sequencing

Imaging

Data processing

Template preparation

Clonally amplified templates from a single DNA molecule

Emulsion PCR

Solid Phase Amplification

Single DNA molecule

Primer immobilized

Template immobilized

Polymerase immobilized

Template preparation


Clonally amplified templates from a single DNA molecule

Emulsion PCR

Solid Phase Amplification

a Roche/454, Life/APG, Polonator Emulsion PCR

One DNA molecule per bead. Clonal amplification to thousands of copies occurs in microreactors in an emulsion




Template preparation

Clonally amplified templates from a single DNA molecule

Emulsion PCR

Solid Phase Amplification

b Illumina/Solexa
Solid-phase amplification
One DNA molecule per cluster



Template preparation

Clonally amplified templates from a single DNA molecule

Emulsion PCR

Solid Phase Amplification


Single DNA molecule

Primer immobilized

Template immobilized


Polymerase immobilized

c Helicos BioSciences: one-pass sequencing
Single molecule: primer immobilized



Billions of primed, single-molecule templates

d Helicos BioSciences: two-pass sequencing
Single molecule: template immobilized



Billions of primed, single-molecule templates

Template preparation

Clonally amplified templates from a single DNA molecule

Emulsion PCR


Solid Phase Amplification

Single DNA molecule

Primer immobilized


Template immobilized

Polymerase immobilized




Sequencing/Imaging


a Illumina/Solexa — Reversible terminators




b




c Helicos BioSciences — Reversible terminators



d







Base calling from raw data




The identity of each base of a cluster is read off from sequential images

Sequencing/Imaging



Sequencing/Imaging

Pacific Biosciences — Real-time sequencing



Nature Reviews | Genetics

Platform	Library/ template preparation	NGS chemistry	Read length (bases)	Run time (days)	Gb per run	Machine cost (US\$)	Pros	Cons	Biological applications	Refs
Roche/454's GS FLX Titanium	Frag, MP/ emPCR	PS	330*	0.35	0.45	500,000	Longer reads improve mapping in repetitive regions; fast run times	High reagent cost; high error rates in homo- polymer repeats	Bacterial and insect genome <i>de novo</i> assemblies; medium scale (<3 Mb) exome capture; 16S in metagenomics	D. Muzny, pers. comm.
Illumina/ Solexa's GA _{II}	Frag, MP/ solid-phase	RTs	75 or 100	4 [‡] , 9 [§]	18 [‡] , 35 [§]	540,000	Currently the most widely used platform in the field	Low multiplexing capability of samples	Variant discovery by whole-genome resequencing or whole-exome capture; gene discovery in metagenomics	D. Muzny, pers. comm.
Life/APG's SOLiD 3	Frag, MP/ emPCR	Cleavable probe SBL	50	7 [‡] , 14 [§]	30 [‡] , 50 [§]	595,000	Two-base encoding provides inherent error correction	Long run times	Variant discovery by whole-genome resequencing or whole-exome capture; gene discovery in metagenomics	D. Muzny, pers. comm.
Polonator G.007	MP only/ emPCR	Non- cleavable probe SBL	26	5 [§]	12 [§]	170,000	Least expensive platform; open source to adapt alternative NGS chemistries	Users are required to maintain and quality control reagents; shortest NGS read lengths	Bacterial genome resequencing for variant discovery	J. Edwards, pers. comm.
Helicos BioSciences HeliScope	Frag, MP/ single molecule	RTs	32*	8 [‡]	37 [‡]	999,000	Non-bias representation of templates for genome and seq-based applications	High error rates compared with other reversible terminator chemistries	Seq-based methods	91
Pacific Biosciences (target release: 2010)	Frag only/ single molecule	Real-time	964*	N/A	N/A	N/A	Has the greatest potential for reads exceeding 1 kb	Highest error rates compared with other NGS chemistries	Full-length transcriptome sequencing; complements other resequencing efforts in discovering large structural variants and haplotype blocks	S. Turner, pers. comm.

*Average read-lengths. [‡]Fragment run. [§]Mate-pair run. Frag, fragment; GA, Genome Analyzer; GS, Genome Sequencer; MP, mate-pair; N/A, not available; NGS, next-generation sequencing; PS, pyrosequencing; RT, reversible terminator; SBL, sequencing by ligation; SOLiD, support oligonucleotide ligation detection.


Personal Genome	Platform	Genomic template libraries	No. of reads (millions)	Read length (bases)	Base coverage (fold)	Assembly	Genome coverage (%) [*]	SNVs in millions (alignment tool)	No. of runs	Estimated cost (US\$)
J. Craig Venter	Automated Sanger	MP from BACs, fosmids & plasmids	31.9	800	7.5	<i>De novo</i>	N/A	3.21	>340,000	70,000,000
James D. Watson	Roche/454	Frag: 500 bp	93.2 [†]	250 [§]	7.4	Aligned [*]	95	3.32 (BLAT)	234	1,000,000 [†]
Yoruban male (NA18507)	Illumina/Solexa	93% MP: 200 bp	3,410 [†]	35	40.6	Aligned [*]	99.9	3.83 (MAQ)	40	250,000 [†]
		7% MP: 1.8 kb	271	35				4.14 (ELAND)		
Han Chinese male	Illumina/Solexa	66% Frag: 150–250 bp	1,921 [†]	35	36	Aligned [*]	99.9	3.07 (SOAP)	35	500,000 [†]
		34% MP: 135 bp & 440 bp	1,029	35						
Korean male (AK1)	Illumina/Solexa	21% Frag: 130 bp & 440 bp	393 [†]	36	27.8	Aligned [*]	99.8	3.45 (GSNAP)	30	200,000 [†]
		79% MP: 130 bp, 390 bp & 2.7 kb	1,156	36,88,106						
Korean male (SJK)	Illumina/Solexa	MP: 100 bp, 200 bp & 300 bp	1,647 [†]	35,74	29.0	Aligned [*]	99.9	3.44 (MAQ)	15	250,000 ^{†,‡}
Yoruban male (NA18507)	Life/APG	9% Frag: 100–500 bp	211 [†]	50	17.9	Aligned [*]	98.6	3.87 (Corona-lite)	9.5	60,000 ^{†,***}
		91% MP: 600–3,500 bp	2,075 [†]	25,50						
Stephen R. Quake	Helicos BioSciences	Frag: 100–500 bp	2,725 [†]	32 [§]	28	Aligned [*]	90	2.81 (IndexDP)	4	48,000 [†]
AML female	Illumina/Solexa	Frag: 150–200 bp ^{††}	2,730 ^{†,††}	32	32.7	Aligned [*]	91	3.81 ^{††} (MAQ)	98	1,600,000
		Frag: 150–200 bp ^{§§}	1,081 ^{†,§§}	35	13.9		83	2.92 ^{§§} (MAQ)	34	
AML male	Illumina/Solexa	MP: 200–250 bp ^{††}	1,620 ^{†,††}	35	23.3	Aligned [*]	98.5	3.46 ^{††} (MAQ)	16.5	500,000
		MP: 200–250 bp ^{§§}	1,351 ^{†,§§}	50	21.3		97.4	3.45 ^{§§} (MAQ)	13.1	
James R. Lupski CMT male	Life/APG	16% Frag: 100–500 bp	238 [†]	35	29.6	Aligned [*]	99.8	3.42 (Corona-lite)	3	75,000 ^{†,††}
		84% MP: 600–3,500 bp	1,211 [†]	25,50						


^{*}A minimum of one read aligning to the National Center for Biotechnology Information build 36 reference genome. [†]Mappable reads for aligned assemblies.


[§]Average read-length. ^{||}D. Wheeler, personal communication. ^{††}Reagent cost only. [‡]S.-M. Ahn, personal communication. ^{***}K. McKernan, personal communication.


^{†††}Tumour sample. ^{§§§}Normal sample. ^{|||}Tumour & normal samples: reagent, instrument, labour, bioinformatics and data storage cost, E. Mardis, 2008.

Sequencing tumour genomes









An additional challenge for research groups is dealing with high end computing infrastructures that are out of reach in terms of both cost and experience for most groups. Unlike the situation genome centers faced 10 years ago where such resources were best managed locally, NGS infrastructures, today are readily available through Internet-based resources. So called "Cloud Computing" resources provide storage, backup and computational resources using "pay-as-you-go" pricing models. These on-demand services, eliminate both IT management issues and costly mistakes that occur when local systems are under or over planned.

